Table 1.
Demographic and clinical characteristics contributed to MACE in ACS patients (n = 1871).
| Characteristics | β (95% CI) | P value | Variants explanation |
|---|---|---|---|
| Age – yrs, mean (±s.d.) | 1.025(1.010–1.040) | <0.001*** | 0.94% |
| Sex, Men – no. (%) | 1.073(0.7404–1.554) | 0.71 | |
| BMI –kg/m2, mean (±s.d.) | 1.016(0.9593–1.077) | 0.58 | |
| Risk factors, n (%) | |||
| Previous MI | 1.075(0.7905–1.461) | 0.65 | |
| Diabetes mellitus | 1.322(0.9657–1.809) | 0.08 | |
| Hypertension | 1.689(1.227–2.325) | <0.001*** | 0.87% |
| Medications used before event | |||
| ACEI_ARB | 1.356(0.8811–2.086) | 0.17 | |
| BBI | 1.178(0.7313–1.896) | 0.5 | |
| CCB | 1.231(0.8747–1.733) | 0.23 | |
| PPI | 1.269(0.9425–1.709) | 0.12 | |
| Statins | 1.069(0.3967–2.882) | 0.89 | |
| Blood metabolites level | |||
| HDLC, mmol/L | 0.8664(0.4562–1.646) | 0.66 | |
| LDLC, mmol/L | 0.8714(0.7305–1.040) | 0.13 | |
| Triglycerides, mmol/L | 0.9466(0.8074–1.110) | 0.5 | |
| HbA1c, % total hemoglobin | 0.8917(0.7732–1.028) | 0.12 | |
| ALT, U/L | 1.002(1–1.005) | 0.06 | |
| AST, U/L | 0.9973(0.993–1.002) | 0.21 | |
| CREA, umol/L | 1.003(1.001–1.005) | <0.001*** | 0.73% |
| CK, U/L | 0.9994(0.9987–1) | 0.28 | |
| CKMB, U/L | 0.9813(0.9622–1.001) | 0.68 | |
P value was calculated by multivariate Cox regression analysis. P < 0.05 was considered a statistically significant difference. β represents exp(coefficient).
BMI, denotes Body-mass index; MI, myocardial infarction; ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker; BBI, β-blockers inhibitors; CCB, calcium channel blockers; PPI, proton pump inhibitors; HDLC, highdensity lipoprotein cholesterol; LDLC, low-density lipoprotein cholesterol; HbA1c, hemoglobin A1c; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CREA, creatinine; CK, creatine kinase and CKMB, creatine kinase MB.
Signif. codes: 0 ‘***‘ 0.001 ‘**‘ 0.01 ‘*‘ 0.05 ‘.’ 0.1 ‘ ‘ 1.